NARA Discovery
Article Details
← Back to Search Results
Journal Article

Effect of Fatty Acid Composition in Polysorbate 80 on the Stability of Therapeutic Protein Formulations

Melissa A. Pegues; Karol Szczepanek; Faruk Sheikh; Seth G. Thacker; Baikuntha Aryal; Mohamed K Ghorab; Steven Wolfgang; Raymond P. Donnelly; Daniela Verthelyi; V. Ashutosh Rao
Pharmaceutical Research · Vol. 38, Issue 11 · pp. 1961-1975 · 2021

Abstract

Purpose Polysorbate excipients are commonly used as surfactants to stabilize therapeutic proteins in formulations. Degradation of polysorbates could lead to particle formation and instability of the drug formulation. We investigated how the fatty acid composition of polysorbate 80 impacts the degradation profile, particle formation, and product stability under stress conditions. Methods Two polysorbate 80-containing therapeutic protein formulations were reformulated with either Polysorbate 80 NF synthesized from a fatty acid mixture that contains mainly oleic acid (≥58%) or a version of polysorbate 80 synthesized with high oleic acid (>98%). Stress conditions, including high temperature and esterase spiking, were applied and changes to both the polysorbate and the therapeutic protein product were investigated for stability, purity, innate immune response and biological activity. Results The addition of esterase and storage at 37°C led to significant hydrolysis of the polysorbate and increases in sub-visible particle formation for both polysorbates tested. The fatty acid composition of polysorbate 80 did not directly alter the stability profile of either therapeutic protein as measured by size exclusion chromatography, or significantly impact innate immune response or biological activity. However, formulations with Polysorbate 80 NF showed greater propensity for sub-visible particle formation under stress conditions. Conclusions These results suggest that composition of fatty acids in polysorbate 80 may be a promoter for sub-visible particulate formation under the stress conditions tested but may not impact protein aggregation or biological activity.

Bibliographic Information

JournalPharmaceutical Research
PublisherSpringer
Publication Date2021-11-01
Publication Year2021
Volume38
Issue11
Pages1961-1975
Document TypeJournal Article
Print ISSN0724-8741
eISSN1573-904X
DOI10.1007/s11095-021-03125-6

Access Information

NARA Access Coverage1984-01-01~Current
Journal Homepagehttps://www.springer.com/journal/11095
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.